Relypsa
NICE says no to AZ and Vifor’s rival hyperkalaemia drugs
Both companies made same error in modelling, says NICE
AZ gets US approval for Veltassa rival Lokelma
But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia
Vifor wins European approval for Veltassa
European Commission approves the drug to treat hyperkalaemia